Grade ≥3 AEs, drug discontinuation, dose reduction, and cumulative dose
| . | Rd-R (n = 101) . | Rd (n = 98) . | All patients (n = 199) . |
|---|---|---|---|
| Hematologic | |||
| At least 1 event | 26 (26) | 20 (20) | 46 (23) |
| Anemia | 9 (9) | 3 (3) | 12 (6) |
| Neutropenia | 21 (21) | 18 (18) | 39 (20) |
| Thrombocytopenia | 4 (4) | 2 (2) | 6 (3) |
| Nonhematologic | |||
| At least 1 event | 33 (33) | 42 (43) | 75 (38) |
| Cardiologic | 2 (2) | 2 (2) | 4 (2) |
| Atrial fibrillation | 1 (1) | 1 (1) | 2 (1) |
| Heart failure | 1 (1) | 1 (1) | 2 (1) |
| Infection | 10 (10) | 12 (12) | 22 (11) |
| Pneumonia | 7 (7) | 4 (4) | 11 (6) |
| Febrile neutropenia | 3 (3) | 1 (1) | 4 (2) |
| Sepsis/septic shock | 0 | 5 (5) | 5 (3) |
| Other | 1 (1) | 3 (3) | 4 (2) |
| Constitutional | 3 (3) | 12 (12) | 15 (8) |
| Fatigue | 2 (2) | 7 (7) | 9 (5) |
| Fever | 0 | 1 (1) | 1 (1) |
| Other | 1 (1) | 6 (6) | 7 (4) |
| Dermatologic | 7 (7) | 3 (3) | 10 (5) |
| Rash | 5 (5) | 2 (2) | 7 (4) |
| Other | 2 (2) | 1 (1) | 3 (2) |
| Gastrointestinal | 5 (5) | 5 (5) | 10 (5) |
| Diarrhea | 3 (3) | 4 (4) | 7 (4) |
| Other | 3 (3) | 2 (2) | 5 (3) |
| Nervous | 2 (2) | 6 (6) | 8 (4) |
| Anxiety | 0 | 2 (2) | 2 (1) |
| Confusion | 0 | 1 (1) | 1 (1) |
| Insomnia | 0 | 1 (1) | 1 (1) |
| Tremor | 0 | 2 (2) | 2 (1) |
| Stroke | 1 (1) | 0 | 1 (1) |
| Other | 1 (1) | 4 (4) | 5 (3) |
| Vascular | 2 (2) | 4 (4) | 6 (3) |
| Thromboembolism | 1 (1) | 4 (4) | 5 (3) |
| Other | 1 (1) | 1 (1) | 2 (1) |
| SPM | 2 (2) | 2 (2) | 4 (2) |
| Pancreatic | 1 (1) | 0 | 1 (1) |
| Hodgkin lymphoma | 0 | 1 (1) | 1 (1) |
| Bowen disease | 1 (1) | 0 | 1 (1) |
| Prostate | 0 | 1 (1) | 1 (1) |
| Lenalidomide | |||
| At least 1 dose reduction, %* | 45 | 62 | 53 |
| Discontinuation for AEs, % | 24 | 30 | 27 |
| Cumulative dose, mg | 5798 | 5408 | 5524 |
| Dexamethasone | |||
| Dose reduction, %† | 17 | 31 | 24 |
| Discontinuation for AEs, %† | 14 | 34 | 24 |
| Cumulative dose,† | 720 | 955 | 740 |
| . | Rd-R (n = 101) . | Rd (n = 98) . | All patients (n = 199) . |
|---|---|---|---|
| Hematologic | |||
| At least 1 event | 26 (26) | 20 (20) | 46 (23) |
| Anemia | 9 (9) | 3 (3) | 12 (6) |
| Neutropenia | 21 (21) | 18 (18) | 39 (20) |
| Thrombocytopenia | 4 (4) | 2 (2) | 6 (3) |
| Nonhematologic | |||
| At least 1 event | 33 (33) | 42 (43) | 75 (38) |
| Cardiologic | 2 (2) | 2 (2) | 4 (2) |
| Atrial fibrillation | 1 (1) | 1 (1) | 2 (1) |
| Heart failure | 1 (1) | 1 (1) | 2 (1) |
| Infection | 10 (10) | 12 (12) | 22 (11) |
| Pneumonia | 7 (7) | 4 (4) | 11 (6) |
| Febrile neutropenia | 3 (3) | 1 (1) | 4 (2) |
| Sepsis/septic shock | 0 | 5 (5) | 5 (3) |
| Other | 1 (1) | 3 (3) | 4 (2) |
| Constitutional | 3 (3) | 12 (12) | 15 (8) |
| Fatigue | 2 (2) | 7 (7) | 9 (5) |
| Fever | 0 | 1 (1) | 1 (1) |
| Other | 1 (1) | 6 (6) | 7 (4) |
| Dermatologic | 7 (7) | 3 (3) | 10 (5) |
| Rash | 5 (5) | 2 (2) | 7 (4) |
| Other | 2 (2) | 1 (1) | 3 (2) |
| Gastrointestinal | 5 (5) | 5 (5) | 10 (5) |
| Diarrhea | 3 (3) | 4 (4) | 7 (4) |
| Other | 3 (3) | 2 (2) | 5 (3) |
| Nervous | 2 (2) | 6 (6) | 8 (4) |
| Anxiety | 0 | 2 (2) | 2 (1) |
| Confusion | 0 | 1 (1) | 1 (1) |
| Insomnia | 0 | 1 (1) | 1 (1) |
| Tremor | 0 | 2 (2) | 2 (1) |
| Stroke | 1 (1) | 0 | 1 (1) |
| Other | 1 (1) | 4 (4) | 5 (3) |
| Vascular | 2 (2) | 4 (4) | 6 (3) |
| Thromboembolism | 1 (1) | 4 (4) | 5 (3) |
| Other | 1 (1) | 1 (1) | 2 (1) |
| SPM | 2 (2) | 2 (2) | 4 (2) |
| Pancreatic | 1 (1) | 0 | 1 (1) |
| Hodgkin lymphoma | 0 | 1 (1) | 1 (1) |
| Bowen disease | 1 (1) | 0 | 1 (1) |
| Prostate | 0 | 1 (1) | 1 (1) |
| Lenalidomide | |||
| At least 1 dose reduction, %* | 45 | 62 | 53 |
| Discontinuation for AEs, % | 24 | 30 | 27 |
| Cumulative dose, mg | 5798 | 5408 | 5524 |
| Dexamethasone | |||
| Dose reduction, %† | 17 | 31 | 24 |
| Discontinuation for AEs, %† | 14 | 34 | 24 |
| Cumulative dose,† | 720 | 955 | 740 |